Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

James C. Yao, Nicola Fazio, Simron Singh, +19

The Lancet

OncologyGastrointestinal OncologyMedicinePathologyCancer Treatment +6

Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension

Ventzislav Petkov, Wilhelm Mosgoeller, Rolf Ziesche, +8

Journal of Clinical Investigation

New DrugHypertensionHeart FailureGastrointestinal Peptide HormonePrimary Pulmonary Hypertension +13

Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET.

Alexander Becherer, Monica Szabó, Georgios Karanikas, +6

PubMed

Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders

Christoph Kornauth, Tea Pemovska, Gregory I. Vladimer, +66

Cancer Discovery

Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron

Christian Müller, Susanna Pongratz, Johann Pidlich, +6

European Journal of Gastroenterology & Hepatology

PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL)

Anna S. Berghoff, Gerda Ricken, Georg Widhalm, +5

Clinical Neuropathology

Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response

Ulrich Jäger, Michael Fridrik, Markus Zeitlinger, +13

Haematologica

Templated nucleotide addition and immunoglobulin JH-gene utilization in t(11;14) junctions: implications for the mechanism of translocation and the origin of mantle cell lymphoma.

Natascha Welzel, Trang Le, Rodrig Marculescu, +12

PubMed

Hematological MalignancyLymphoid NeoplasiaMantle Cell LymphomaMedicineMalignant Blood Disorder +11

Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Marianne Pavel, Simron Singh, Jonathan Strosberg, +21

The Lancet Oncology

Gastrointestinal OncologyHealth-related QualityMedicineLung Neuroendocrine TumoursCancer Management +6

Palliative chemotherapy for recurrent and metastatic esophageal cancer.

Birgit Grünberger, Markus Raderer, Manuela Schmidinger, +1

PubMed

Advanced Esophageal CancerEsophageal CancerGastrointestinal OncologyMedicineCancer Management +9